abrdn Life Sciences Investors (HQL)
abrdn Life Sciences Investors
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | 17.51 | 17.74 | 17.48 | 17.49 | 57,156 |
| Nov 17, 2026 | 17.75 | 17.77 | 17.28 | 17.62 | 138,690 |
| Nov 16, 2026 | 18.51 | 19.09 | 17.76 | 17.81 | 296,927 |
| Nov 13, 2026 | 18.34 | 18.49 | 17.88 | 18.28 | 107,218 |
| Nov 12, 2026 | 18.81 | 18.81 | 18.23 | 18.34 | 91,731 |
| Nov 11, 2026 | 18.77 | 18.95 | 18.60 | 18.95 | 77,996 |
| Nov 10, 2026 | 18.59 | 18.79 | 18.24 | 18.67 | 100,257 |
| Nov 9, 2026 | 18.21 | 18.70 | 17.97 | 18.66 | 136,358 |
| Nov 6, 2026 | 17.36 | 18.11 | 17.36 | 18.09 | 102,728 |
| Nov 5, 2026 | 18.36 | 18.36 | 17.30 | 17.36 | 157,085 |
| Nov 4, 2026 | 18.56 | 18.56 | 17.90 | 18.36 | 123,120 |
| Nov 3, 2026 | 17.85 | 18.29 | 17.85 | 18.12 | 130,095 |
| Nov 2, 2026 | 18.42 | 19.00 | 17.89 | 17.98 | 79,334 |
| Oct 30, 2026 | 18.77 | 18.77 | 18.25 | 18.44 | 86,549 |
| Oct 29, 2026 | 18.53 | 18.82 | 18.40 | 18.74 | 102,863 |
| Oct 28, 2026 | 18.07 | 18.31 | 17.99 | 18.28 | 92,974 |
| Oct 27, 2026 | 17.67 | 18.00 | 17.66 | 18.00 | 166,843 |
| Oct 26, 2026 | 17.85 | 17.89 | 17.60 | 17.70 | 70,693 |
| Oct 23, 2026 | 17.99 | 17.99 | 17.51 | 17.73 | 60,790 |
| Oct 22, 2026 | 17.91 | 18.10 | 17.81 | 17.95 | 118,565 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Purchase | 527 | $10.5K | Jul 16, 2026 | |
| Director | Purchase | 7.9K | $133.8K | Dec 16, 2025 | |
| 10% Owner | Sale | 41.6K | $588.5K | Sep 22, 2025 | |
| 10% Owner | Sale | 7.0K | $98.5K | Sep 19, 2025 | |
| 10% Owner | Sale | 40.2K | $565.7K | Sep 18, 2025 | |
| 10% Owner | Sale | 24.3K | $340.3K | Sep 17, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
First Trust Portfolios L.P. · also on 13F· joint filing· may incl. warrants· filed Oct 2026 | 3.6M | 11.7% | 13G |
MORGAN STANLEY | 2.1M | 6.8% | 13F |
Penserra Capital Management LLC | 838.9K | 2.8% | 13F |
RAYMOND JAMES FINANCIAL INC | 740.1K | 2.4% | 13F |
LPL Financial LLC | 552.8K | 1.8% | 13F |
NEEDHAM INVESTMENT MANAGEMENT LLC | 443.0K | 1.5% | 13F |
FLAGSHIP HARBOR ADVISORS, LLC | 417.4K | 1.4% | 13F |
Allspring Global Investments Holdings, LLC | 416.0K | 1.4% | 13F |
Advisors Asset Management, Inc. | 208.9K | 0.7% | 13F |
AMERIPRISE FINANCIAL INC | 168.6K | 0.6% | 13F |
Insiders
- Mahai Chris LaVictoireDirector
- Pittard ChristianDirector
- Saba Capital Management, L.P.10% Owner
Top institutional holders
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide.
Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors.
It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
based on 30.41M shares outstanding
30d Avg
113.37K
60d Avg
120.38K
90d Avg
124.45K
abrdn Life Sciences Investors (NYSE: HQL) traded at $17.49 on Nov 18, 2026, down 0.76% from the previous close of $17.62. 52-week range: $15.66 to $22.67.